Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%

Healthcare

Page 93
  1. Dec 01, 2025 · 15:37 · RKV

    Rakovina's Q3 R&D expenses at $1.1-million

    Rakovina's Q3 R&D expenses at $1.1-million

    01
  2. Dec 01, 2025 · 14:42 · BNXT

    Bionxt to acquire IP to sublingual drug formulation

    Bionxt to acquire IP to sublingual drug formulation

    02
  3. Dec 01, 2025 · 13:45 · KDA

    KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

    KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

    03
  4. Dec 01, 2025 · 07:28 · CRDL

    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

    04
  5. Nov 28, 2025 · 21:00 · MIR

    MedMira Reports FY2025 Fourth Quarter and Year End Financial Results

    MedMira Reports FY2025 Fourth Quarter and Year End Financial Results

    05
  6. Nov 28, 2025 · 20:25 · AGN

    Algernon Health closes second tranche of financing

    Algernon Health closes second tranche of financing

    06
  7. Nov 28, 2025 · 19:51 · AGN

    Algernon Closes Second Tranche of Private Placement Financing

    Algernon Closes Second Tranche of Private Placement Financing

    07
  8. Nov 28, 2025 · 19:44 · PCRX

    Pharmacorp Rx Inc. Reports Q3 2025 Financial Results

    Pharmacorp Rx Inc. Reports Q3 2025 Financial Results

    08
  9. Nov 28, 2025 · 18:05 · CYTO

    Cytophage Announces Closing of Non-Brokered Private Placement and Filing of Q3 Financials

    Cytophage Announces Closing of Non-Brokered Private Placement and Filing of Q3 Financials

    09
  10. Nov 28, 2025 · 16:28 · PRN

    Profound Medical to roll out Tulsa-AI BPH module

    Profound Medical to roll out Tulsa-AI BPH module

    10
  11. Nov 28, 2025 · 16:23 · NURS

    Hydreight closes acquisition of 5% of Perfect Scripts

    Hydreight closes acquisition of 5% of Perfect Scripts

    11
  12. Nov 28, 2025 · 12:24 · KNE

    Kane Biotech loses $607,345 in Q3 2025

    Kane Biotech loses $607,345 in Q3 2025

    12
  13. Nov 28, 2025 · 09:30 · QNTM

    REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

    REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

    13
  14. Nov 28, 2025 · 09:15 · NRX

    NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    14
← Newer Older →